1. In this phase 2 randomized controlled trial, weekly subcutaneous mezagitimab was well-tolerated and associated with symptomatic improvement among patients ...
1. CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2. Treatment-related ...
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission ...
1. In this target trial emulation study, denosumab was associated with an increased risk of major adverse cardiovascular events compared ...
The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients with relapsed/refractory ...
Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade ...
1. In this randomized controlled trial, in patients diagnosed with migraine, it was found that administration of a monoclonal antibody ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Compared to the placebo, patients treated with Kisunla had a 35% slower cognitive and functional decline at 18 months of ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.
